Cheaper semaglutides as patent ends is good news for diabetics. But lax regulation also means a risk of abuse by those desperate to lose weight
In a world obsessed with physical appearance, it’s easy to see why these drugs are in demand.
The United States has been Novo’s primary market for both Ozempic and Wegovy, accounting for over 60 per cent of sales for weight-loss jabs. That is set to change as India and China enter the market with generics.
